Compare Amgen, Inc. (AMGN) vs Monolithic Power Systems Inc (MPWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Monolithic Power Systems Inc — how do they compare? Amgen, Inc. trades at $416.99 (market cap $224.14B), while Monolithic Power Systems Inc trades at $1,424 (market cap $68.90B). The key difference: Amgen, Inc. is far larger — about 3.3× Monolithic Power Systems Inc's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | MPWR | |
|---|---|---|
Market Cap | $224.14B | $68.90B |
Sector | Health | Utilities |
52-Week High | $417.20 | $1.69K |
52-Week Low | $271.18 | $820.74 |
Enterprise Value | $267.45B | $67.51B |
Dividend Yield | 2.43% | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.
Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.
MPWR is trading at $1,437.94, up 4.12% today, reflecting strong momentum after recent earnings beats. The stock shows a bullish technical trend with support at $1,386 and resistance at $1,425. Fundamentally, Q2 2026 revenue surged to $980.6M, driven by 164.3% growth in Enterprise Data, with net income margin expanding to 24.5%. Analyst sentiment is overwhelmingly positive, with 88% recommending Buy and a consensus price target of $1,870.
Outlook remains favorable given robust AI-driven demand and upward earnings revisions, but risks include high valuation multiples (P/E 85.55) and potential double-ordering concerns. The stock offers growth exposure but requires monitoring of execution and competitive pressures in the semiconductor sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →
